All In Biotech

Drug Trial Radar · NCT06662097

A Study of Bevonescein in Patients Undergoing Abdominopelvic Surgery

Multicenter Open-Label Feasibility Study of Intraoperative Nerve and Ureter Visualization With Bevonescein in Patients Undergoing Minimally Invasive Abdominopelvic Surgery

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

27

Actual

Start

Oct 16, 2024

Primary completion

Jan 2, 2026

Study completion Jan 28, 2026

Sponsor

Lead sponsor
Alume Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Oct 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Feasibility study of Bevonescein to highlight Nerves and Ureter in patients undergoing Minimally Invasive Surgery

Conditions

  • Surgery
  • Nerve Injury
  • Imaging

Interventions

  • BevonesceinDrug

    Bevonescein is a sterile solution that is intravenously administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Fluorescence System SurveyTime frame: Day 1

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of California San Diego

    San Diego, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.